Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease

G. Vendemiale, E. Altomare, T. Trizio, C. Le Grazie, C. Di Padova, M. T. Salerno, V. Carrieri, O. Albano

Research output: Contribution to journalArticlepeer-review


S-Adenosyl-l-methionine (SAMe) is a physiologic precursor of thiols and sulfurated compounds, which are known to be decreased in patients with liver disease. The effect of its administration on the hepatic glutathione content of liver patients was investigated. Four groups of subjects were selected: a) 9 patients with alcoholic liver disease treated with SAMe (1.2g/day orally for 6 months); b) 7 patients with nonalcoholic liver disease treated as above; c) 8 placebo-treated patients with alcoholic liver disease; and d) 15 normal subjects as a control group. Total and oxidized glutathione were assayed by high-performance liquid chromatography of liver biopsy specimens before and after the treatment period. In all patients pre-treatment hepatic glutathione was significantly decreased as compared with controls. SAMe therapy resulted in a significant increase of hepatic glutathione levels both in patients with alcoholic and in those with non-alcoholic liver diseases as compared with placebo-treated patients. SAMe may therefore exert an important role in reversing hepatic glutathione depletion in patients with liver disease.

Original languageEnglish
Pages (from-to)407-415
Number of pages9
JournalScandinavian Journal of Gastroenterology
Issue number4
Publication statusPublished - 1989


  • Alcohol
  • Glutathione
  • Liver disease
  • S-adenosyl-l-methionine

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Effects of oral s-adenosyl-l-methionine on hepatic glutathione in patients with liver disease'. Together they form a unique fingerprint.

Cite this